

# You-Hua Xie

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3552680/publications.pdf>

Version: 2024-02-01

100  
papers

5,574  
citations

117625

34  
h-index

98798

67  
g-index

108  
all docs

108  
docs citations

108  
times ranked

10252  
citing authors

#	ARTICLE	IF	CITATIONS
1	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 1652-1661.	12.0	24
2	An ultrapotent pan- $\beta$ -coronavirus lineage B ( $\beta$ -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	11.0	25
3	Advancements in detection of SARS-CoV-2 infection for confronting COVID-19 pandemics. <i>Laboratory Investigation</i> , 2022, 102, 4-13.	3.7	36
4	Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2. <i>Cell Research</i> , 2022, 32, 24-37.	12.0	98
5	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. <i>Cell Research</i> , 2022, 32, 269-287.	12.0	54
6	Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein. <i>Emerging Microbes and Infections</i> , 2022, 11, 351-367.	6.5	19
7	Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 53, 116523.	3.0	13
8	Neutralizing SARS-CoV-2 by dimeric side chain-to-side chain cross-linked ACE2 peptide mimetics. <i>Chemical Communications</i> , 2022, 58, 1804-1807.	4.1	3
9	High mobility group AT-hook 1 (HMGA1) is an important positive regulator of hepatitis B virus (HBV) that is reciprocally upregulated by HBV X protein. <i>Nucleic Acids Research</i> , 2022, 50, 2157-2171.	14.5	11
10	SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network. <i>EBioMedicine</i> , 2022, 76, 103861.	6.1	24
11	Rapid and ultrasensitive electromechanical detection of ions, biomolecules and SARS-CoV-2 RNA in unamplified samples. <i>Nature Biomedical Engineering</i> , 2022, 6, 276-285.	22.5	153
12	Monocytic MDSCs homing to thymus contribute to age-related CD8+ T cell tolerance of HBV. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	10
13	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. <i>Cell</i> , 2022, 185, 1389-1401.e18.	28.9	82
14	Entry Inhibitors of Hepatitis B and D Viruses. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1366, 199-205.	1.6	1
15	Establishment and characterization of a new cell culture system for hepatitis B virus replication and infection. <i>Virologica Sinica</i> , 2022, 37, 558-568.	3.0	5
16	Survival of SARS-CoV-2 in artificial seawater and on the surface of inanimate materials. <i>Journal of Medical Virology</i> , 2022, 94, 3982-3987.	5.0	19
17	Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. <i>Nature Microbiology</i> , 2022, 7, 1063-1074.	13.3	63
18	Engineered trimeric ACE2 binds viral spike protein and locks it in a Three-up conformation to potently inhibit SARS-CoV-2 infection. <i>Cell Research</i> , 2021, 31, 98-100.	12.0	76

#	ARTICLE	IF	CITATIONS
19	Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2. <i>Science Bulletin</i> , 2021, 66, 925-936.	9.0	29
20	A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge. <i>Emerging Microbes and Infections</i> , 2021, 10, 1555-1573.	6.5	6
21	Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. <i>Nature Communications</i> , 2021, 12, 264.	12.8	81
22	Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. <i>MAbs</i> , 2021, 13, 1953683.	5.2	20
23	Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. <i>Nature Communications</i> , 2021, 12, 866.	12.8	73
24	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. <i>Cell Reports</i> , 2021, 34, 108699.	6.4	110
25	A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry. <i>Nature Communications</i> , 2021, 12, 961.	12.8	204
26	Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 131.	17.1	52
27	A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2. <i>Frontiers in Immunology</i> , 2021, 12, 653189.	4.8	20
28	Functional and genetic analysis of viral receptor ACE2 orthologs reveals a broad potential host range of SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	168
29	Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry. <i>PLoS Pathogens</i> , 2021, 17, e1009392.	4.7	34
30	Transfected DNA is targeted by STING-mediated restriction. <i>Biochemical and Biophysical Research Communications</i> , 2021, 549, 207-213.	2.1	1
31	Prior transient exposure to interleukin-21 delivered by recombinant adeno-associated virus vector protects mice from hepatitis B virus persistence. <i>Antiviral Research</i> , 2021, 190, 105076.	4.1	5
32	Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 288.	17.1	38
33	Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection. <i>Cell Discovery</i> , 2021, 7, 71.	6.7	26
34	Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates. <i>Frontiers in Microbiology</i> , 2021, 12, 626553.	3.5	90
35	AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. <i>Cell Research</i> , 2021, 31, 126-140.	12.0	356
36	Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants. <i>Genome Medicine</i> , 2021, 13, 164.	8.2	42

#	ARTICLE	IF	CITATIONS
37	Direct SARS-CoV-2 Nucleic Acid Detection by Y-Shaped DNA Dual-Probe Transistor Assay. <i>Journal of the American Chemical Society</i> , 2021, 143, 17004-17014.	13.7	79
38	Selection and Identification of Novel Antibacterial Agents against Planktonic Growth and Biofilm Formation of <i>Enterococcus faecalis</i> . <i>Journal of Medicinal Chemistry</i> , 2021, 64, 15037-15052.	6.4	8
39	Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants. <i>Vaccine</i> , 2021, 39, 7001-7011.	3.8	20
40	Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants. <i>Nature Communications</i> , 2021, 12, 6304.	12.8	42
41	Rapid SARS-CoV-2 Nucleic Acid Testing and Pooled Assay by Tetrahedral DNA Nanostructure Transistor. <i>Nano Letters</i> , 2021, 21, 9450-9457.	9.1	33
42	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 378.	17.1	26
43	Restriction of exogenous DNA expression by SAMHD1. <i>Science Bulletin</i> , 2020, 65, 573-586.	9.0	2
44	Epidemiology and Genetic Characterization of Classical Human Astrovirus Infection in Shanghai, 2015-2016. <i>Frontiers in Microbiology</i> , 2020, 11, 570541.	3.5	11
45	Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. <i>Virologica Sinica</i> , 2020, 35, 857-860.	3.0	39
46	Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 27141-27147.	7.1	173
47	Occurrence and quantification of Anelloviruses and Herpesviruses in gingival tissue in Chinese Shanghai sub-population. <i>BMC Oral Health</i> , 2020, 20, 196.	2.3	10
48	Proscillaridin A inhibits hepatocellular carcinoma progression through inducing mitochondrial damage and autophagy. <i>Acta Biochimica Et Biophysica Sinica</i> , 2020, 53, 19-28.	2.0	4
49	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 282.	17.1	149
50	SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. <i>Journal of Hematology and Oncology</i> , 2020, 13, 120.	17.0	505
51	Survival of SARS-COV-2 under liquid medium, dry filter paper and acidic conditions. <i>Cell Discovery</i> , 2020, 6, 57.	6.7	12
52	Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement. <i>Cell Discovery</i> , 2020, 6, 61.	6.7	52
53	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. <i>JAMA Internal Medicine</i> , 2020, 180, 1356.	5.1	211
54	Characterization of IL-21-expressing recombinant hepatitis B virus (HBV) as a therapeutic agent targeting persisting HBV infection. <i>Theranostics</i> , 2020, 10, 5600-5612.	10.0	16

#	ARTICLE	IF	CITATIONS
55	Identification of Human Single-Domain Antibodies against SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020, 27, 891-898.e5.	11.0	227
56	Microbial and metabolomic analysis of gingival crevicular fluid in general chronic periodontitis patients: lessons for a predictive, preventive, and personalized medical approach. <i>EPMA Journal</i> , 2020, 11, 197-215.	6.1	40
57	Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection. <i>Cell Reports</i> , 2020, 32, 107918.	6.4	148
58	Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids. <i>Protein and Cell</i> , 2020, 11, 771-775.	11.0	313
59	Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology. <i>PLoS Pathogens</i> , 2020, 16, e1008340.	4.7	11
60	IL-21-based therapies induce clearance of hepatitis B virus persistence in mouse models. <i>Theranostics</i> , 2019, 9, 3798-3811.	10.0	15
61	&lt;p&gt;A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells&lt;/p&gt;. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 4029-4044.	6.7	58
62	Establishment of an in vitro reporter system for screening HBx-targeting molecules. <i>Acta Biochimica Et Biophysica Sinica</i> , 2019, 51, 431-440.	2.0	3
63	Characterization and engineering of broadly reactive monoclonal antibody against hepatitis B virus X protein that blocks its interaction with DDB1. <i>Scientific Reports</i> , 2019, 9, 20323.	3.3	7
64	A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice. <i>Antiviral Research</i> , 2018, 149, 48-57.	4.1	22
65	Copolymer micelles function as pH-responsive nanocarriers to enhance the cytotoxicity of a HER2 aptamer in HER2-positive breast cancer cells. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 537-553.	6.7	38
66	Capable Infection of Hepatitis B Virus in Diffuse Large B-cell Lymphoma. <i>Journal of Cancer</i> , 2018, 9, 1575-1581.	2.5	24
67	Identification of a Torque Teno Mini Virus (TTMV) in Hodgkinâ€™s Lymphoma Patients. <i>Frontiers in Microbiology</i> , 2018, 9, 1680.	3.5	15
68	A Novel Phage PD-6A3, and Its Endolysin Ply6A3, With Extended Lytic Activity Against <i>Acinetobacter baumannii</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 3302.	3.5	79
69	Hepatitis B virus X protein is capable of down-regulating protein level of host antiviral protein APOBEC3G. <i>Scientific Reports</i> , 2017, 7, 40783.	3.3	29
70	Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis. <i>EBioMedicine</i> , 2017, 20, 70-78.	6.1	7
71	Association of Mutations in Toll-like Receptor 2 Signaling Genes With Fulminant Form of Hepatitis Bâ€™-Related Acute Liver Failure. <i>Journal of Infectious Diseases</i> , 2017, 215, 1221-1230.	4.0	4
72	Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1018, 11-21.	1.6	130

#	ARTICLE	IF	CITATIONS
73	ABCB5 promotes melanoma metastasis through enhancing NF- $\kappa$ B p65 protein stability. <i>Biochemical and Biophysical Research Communications</i> , 2017, 492, 18-26.	2.1	28
74	Hepatitis B virus persistence in mice reveals IL-21 and IL-33 as regulators of viral clearance. <i>Nature Communications</i> , 2017, 8, 2119.	12.8	36
75	Prospero-related homeobox 1 drives angiogenesis of hepatocellular carcinoma through selectively activating interleukin-8 expression. <i>Hepatology</i> , 2017, 66, 1894-1909.	7.3	31
76	Luteolin-7-O-Glucoside Present in Lettuce Extracts Inhibits Hepatitis B Surface Antigen Production and Viral Replication by Human Hepatoma Cells in Vitro. <i>Frontiers in Microbiology</i> , 2017, 8, 2425.	3.5	20
77	Hepatocyte nuclear factor 1 $\alpha$ downregulates HBV gene expression and replication by activating the NF- $\kappa$ B signaling pathway. <i>PLoS ONE</i> , 2017, 12, e0174017.	2.5	21
78	Prox1 represses IL-2 gene expression by interacting with NFAT2. <i>Oncotarget</i> , 2017, 8, 69422-69434.	1.8	3
79	Engineering Hepadnaviruses as Reporter-Expressing Vectors: Recent Progress and Future Perspectives. <i>Viruses</i> , 2016, 8, 125.	3.3	4
80	Re-Designed Recombinant Hepatitis B Virus Vectors Enable Efficient Delivery of Versatile Cargo Genes to Hepatocytes with Improved Safety. <i>Viruses</i> , 2016, 8, 129.	3.3	10
81	Comparative Transcriptomic Analysis of Primary Duck Hepatocytes Provides Insight into Differential Susceptibility to DHBV Infection. <i>PLoS ONE</i> , 2016, 11, e0149702.	2.5	6
82	Efficient Inhibition of Hepatitis B Virus Infection by a preS1-binding Peptide. <i>Scientific Reports</i> , 2016, 6, 29391.	3.3	11
83	Nuclear factor Y regulates ancient budgerigar hepadnavirus core promoter activity. <i>Biochemical and Biophysical Research Communications</i> , 2016, 478, 825-830.	2.1	3
84	Unimpaired immunogenicity of yeast-expressed hepatitis B surface antigen stored at elevated temperatures. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 1094-1100.	2.0	3
85	Short-term intratracheal use of PEG-modified IL-2 and glucocorticoid persistently alleviates asthma in a mouse model. <i>Scientific Reports</i> , 2016, 6, 31562.	3.3	14
86	A human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effect. <i>MAbs</i> , 2016, 8, 468-477.	5.2	30
87	Impact of an Altered PROX1 Expression on Clinicopathology, Prognosis and Progression in Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e95996.	2.5	9
88	Quantitative Proteomic Analysis of Exosome Protein Content Changes Induced by Hepatitis B Virus in Huh-7 Cells Using SILAC Labeling and LC-MS/MS. <i>Journal of Proteome Research</i> , 2014, 13, 5391-5402.	3.7	66
89	Adenoviral Delivery of Recombinant Hepatitis B Virus Expressing Foreign Antigenic Epitopes for Immunotherapy of Persistent Viral Infection. <i>Journal of Virology</i> , 2014, 88, 3004-3015.	3.4	10
90	A broadly reactive monoclonal antibody detects multiple genotypes of hepatitis B virus X protein. <i>Archives of Virology</i> , 2014, 159, 2731-2735.	2.1	11

#	ARTICLE	IF	CITATIONS
91	Recombinant Covalently Closed Circular Hepatitis B Virus DNA Induces Prolonged Viral Persistence in Immunocompetent Mice. <i>Journal of Virology</i> , 2014, 88, 8045-8056.	3.4	81
92	PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1 $\alpha$ expression and protein stability. <i>Hepatology</i> , 2013, 58, 692-705.	7.3	86
93	Novel Recombinant Hepatitis B Virus Vectors Efficiently Deliver Protein and RNA Encoding Genes into Primary Hepatocytes. <i>Journal of Virology</i> , 2013, 87, 6615-6624.	3.4	39
94	The First Full-Length Endogenous Hepadnaviruses: Identification and Analysis. <i>Journal of Virology</i> , 2012, 86, 9510-9513.	3.4	26
95	Development of novel therapeutics for chronic hepatitis B. <i>Virologica Sinica</i> , 2010, 25, 294-300.	3.0	8
96	Identification of recombination between subgenotypes IA and IB of hepatitis A virus. <i>Virus Genes</i> , 2010, 40, 222-224.	1.6	23
97	Prospero-related homeobox protein (Prox1) inhibits hepatitis B virus replication through repressing multiple cis regulatory elements. <i>Journal of General Virology</i> , 2009, 90, 1246-1255.	2.9	31
98	Characterization of a novel isoform of murine interferon regulatory factor 3. <i>Biochemical and Biophysical Research Communications</i> , 2008, 377, 384-388.	2.1	7
99	Identification and Characterization of Peptides That Interact with Hepatitis B Virus via the Putative Receptor Binding Site. <i>Journal of Virology</i> , 2007, 81, 4244-4254.	3.4	38
100	Gene-expression profiles of a hepatitis B small surface antigen-secreting cell line reveal upregulation of lymphoid enhancer-binding factor 1. <i>Journal of General Virology</i> , 2007, 88, 2966-2976.	2.9	19